Clinical utility of the Fibrosis-4 index for predicting mortality in patients with heart failure with or without metabolic dysfunction-associated steatotic liver disease: a prospective cohort study

IF 13.6 Q1 HEALTH CARE SCIENCES & SERVICES Lancet Regional Health-Europe Pub Date : 2024-11-30 DOI:10.1016/j.lanepe.2024.101153
Joost Boeckmans , Jürgen H. Prochaska , Alexander Gieswinkel , Michael Böhm , Philipp S. Wild , Jörn M. Schattenberg
{"title":"Clinical utility of the Fibrosis-4 index for predicting mortality in patients with heart failure with or without metabolic dysfunction-associated steatotic liver disease: a prospective cohort study","authors":"Joost Boeckmans ,&nbsp;Jürgen H. Prochaska ,&nbsp;Alexander Gieswinkel ,&nbsp;Michael Böhm ,&nbsp;Philipp S. Wild ,&nbsp;Jörn M. Schattenberg","doi":"10.1016/j.lanepe.2024.101153","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The liver–heart axis potentially influences the risk of mortality in patients with heart failure. We aimed to identify the clinical utility of the fibrosis-4 (FIB-4) index in patients with heart failure for predicting mortality in the context of metabolic dysfunction-associated steatotic liver disease (MASLD).</div></div><div><h3>Methods</h3><div>Patients with heart failure and a subsample of healthy participants were enrolled in the MyoVasc study (<span><span>NCT04064450</span><svg><path></path></svg></span>) and followed for nine years. Participants with excessive alcohol consumption were excluded. The Fatty Liver Index (FLI) and FIB-4 index were used to classify MASLD and hepatic fibrosis, respectively. Data were adjusted for potential confounders. The primary endpoint was all-cause mortality.</div></div><div><h3>Findings</h3><div>2726 participants, including 172 healthy individuals, were included in the study. The participants had a mean age of 64.4 ± 11.2 years and a median FIB-4 index of 1.59 (interquartile range [1.17; 2.17]). There were 532 deaths. The FIB-4 index was predictive for all-cause mortality (hazard ratio (HR) 1.341, 95% confidence interval (CI) [1.273; 1.412], p &lt; 0.0001). The HRs and 95% CIs for the FIB-4 index in FLI categories were 1.597 [1.256; 2.031] (p = 0.00013, FLI &lt;30), 1.802 [1.519; 2.138] (p &lt; 0.0001, FLI 30–60), and 1.292 [1.215; 1.374] (p &lt; 0.0001, FLI ≥60). The interaction term for the FIB-4 index with FLI ≥60 (reference FLI &lt;30) was HR 0.774 [0.617; 0.972] (p = 0.027), indicating a smaller impact of the FIB-4 index in FLI ≥60 than in FLI &lt;30 (HR 1.664 [1.333; 2.077], p &lt; 0.0001). Multivariable linear regressions revealed relevant independent relationships between the FIB-4 index and N-terminal pro-B-type natriuretic peptide, systolic dysfunction, diastolic dysfunction and left ventricular hypertrophy in participants with a FLI below 60.</div></div><div><h3>Interpretation</h3><div>In patients with heart failure, the FIB-4 index predicts all-cause mortality and relates to cardiac functional and structural changes, especially in those without MASLD.</div></div><div><h3>Funding</h3><div>Johannes Gutenberg-University Mainz.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"48 ","pages":"Article 101153"},"PeriodicalIF":13.6000,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Regional Health-Europe","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666776224003223","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Background

The liver–heart axis potentially influences the risk of mortality in patients with heart failure. We aimed to identify the clinical utility of the fibrosis-4 (FIB-4) index in patients with heart failure for predicting mortality in the context of metabolic dysfunction-associated steatotic liver disease (MASLD).

Methods

Patients with heart failure and a subsample of healthy participants were enrolled in the MyoVasc study (NCT04064450) and followed for nine years. Participants with excessive alcohol consumption were excluded. The Fatty Liver Index (FLI) and FIB-4 index were used to classify MASLD and hepatic fibrosis, respectively. Data were adjusted for potential confounders. The primary endpoint was all-cause mortality.

Findings

2726 participants, including 172 healthy individuals, were included in the study. The participants had a mean age of 64.4 ± 11.2 years and a median FIB-4 index of 1.59 (interquartile range [1.17; 2.17]). There were 532 deaths. The FIB-4 index was predictive for all-cause mortality (hazard ratio (HR) 1.341, 95% confidence interval (CI) [1.273; 1.412], p < 0.0001). The HRs and 95% CIs for the FIB-4 index in FLI categories were 1.597 [1.256; 2.031] (p = 0.00013, FLI <30), 1.802 [1.519; 2.138] (p < 0.0001, FLI 30–60), and 1.292 [1.215; 1.374] (p < 0.0001, FLI ≥60). The interaction term for the FIB-4 index with FLI ≥60 (reference FLI <30) was HR 0.774 [0.617; 0.972] (p = 0.027), indicating a smaller impact of the FIB-4 index in FLI ≥60 than in FLI <30 (HR 1.664 [1.333; 2.077], p < 0.0001). Multivariable linear regressions revealed relevant independent relationships between the FIB-4 index and N-terminal pro-B-type natriuretic peptide, systolic dysfunction, diastolic dysfunction and left ventricular hypertrophy in participants with a FLI below 60.

Interpretation

In patients with heart failure, the FIB-4 index predicts all-cause mortality and relates to cardiac functional and structural changes, especially in those without MASLD.

Funding

Johannes Gutenberg-University Mainz.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
纤维化-4指数预测伴有或不伴有代谢功能障碍相关脂肪变性肝病的心力衰竭患者死亡率的临床应用:一项前瞻性队列研究
背景:肝-心轴可能影响心力衰竭患者的死亡风险。我们旨在确定纤维化-4 (FIB-4)指数在心衰患者中用于预测代谢功能障碍相关脂肪变性肝病(MASLD)患者死亡率的临床应用。MyoVasc研究(NCT04064450)纳入心力衰竭患者和健康参与者的亚样本,随访9年。过量饮酒的参与者被排除在外。采用脂肪肝指数(FLI)和FIB-4指数分别对MASLD和肝纤维化进行分类。针对潜在的混杂因素对数据进行了调整。主要终点是全因死亡率。研究结果包括2726名参与者,其中包括172名健康个体。参与者的平均年龄为64.4±11.2岁,中位FIB-4指数为1.59(四分位数间距[1.17;2.17])。共有532人死亡。FIB-4指数可预测全因死亡率(危险比(HR) 1.341, 95%可信区间(CI) [1.273;[1.42], p <;0.0001)。FLI分类FIB-4指数的hr和95% ci分别为1.597 [1.256;2.031] (p = 0.00013, FLI <30), 1.802 [1.519;2.88] [p <;0.0001, FLI 30-60)和1.292 [1.215;[1.374] [p <;0.0001, fli≥60)。当FLI≥60(参考FLI <;30)时,FIB-4指数的相互作用项HR为0.774 [0.617;0.972] (p = 0.027),表明FLI≥60时FIB-4指数的影响小于FLI≥30时(HR 1.664 [1.333;[02.07], p <;0.0001)。多变量线性回归显示,在FLI低于60的受试者中,FIB-4指数与n端前b型利钠肽、收缩功能障碍、舒张功能障碍和左室肥厚之间存在相关的独立关系。在心力衰竭患者中,FIB-4指数预测全因死亡率,并与心脏功能和结构变化有关,特别是在没有MASLD的患者中。资助美因茨约翰内斯·古腾堡大学。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
19.90
自引率
1.40%
发文量
260
审稿时长
9 weeks
期刊介绍: The Lancet Regional Health – Europe, a gold open access journal, is part of The Lancet's global effort to promote healthcare quality and accessibility worldwide. It focuses on advancing clinical practice and health policy in the European region to enhance health outcomes. The journal publishes high-quality original research advocating changes in clinical practice and health policy. It also includes reviews, commentaries, and opinion pieces on regional health topics, such as infection and disease prevention, healthy aging, and reducing health disparities.
期刊最新文献
On-label alcohol beverage warnings in Ireland- setting a standard for Europe. C-reactive protein testing in primary care and antibiotic use in children with acute respiratory tract infections in Kyrgyzstan: an open-label, individually randomised, controlled trial. Associations between degree of food processing and all-cause and cause-specific mortality: a multicentre prospective cohort analysis in 9 European countries. Dynamic association of antimicrobial resistance in urinary isolates of Escherichia coli and Klebsiella pneumoniae between primary care and hospital settings in the Netherlands (2008-2020): a population-based study. We need evidence-based futility thresholds to transplant grade-3 acute on chronic liver failure patients with poor respiratory, haemodynamic, and metabolic parameters.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1